Jennifer Stacey talks about AI in Healthcare. Enhancing but not replacing the human element

The conversation delves into the career trajectory and evolution of the guest, followed by a discussion on the evolution of CROs and sponsors. It then explores the preferred provider model, challenges in feasibility and enrollment, feasibility and protocol optimization, quality by design, and enrollment challenges. The key takeaways include the importance of communication, the quality by design approach, and the need for a robust feasibility study.

Takeaways

• Communication is key
• Quality by design approach
• Robust feasibility study

Chapters

• 00:00 Career Trajectory and Evolution
• 05:33 Preferred Provider Model
• 15:02 Feasibility and Protocol Optimization
• 20:23 Quality by Design and Enrollment Challenges

Jennifer Stacey shares her extensive career journey in clinical research and healthcare optimization, highlighting the pivotal role of real-world data and real-world evidence. She discusses the challenges faced, the evolution of the industry, and the use of AI and NLP in processing real-world data, providing valuable insights into the future of healthcare research and optimization.

Takeaways:

• Real-world data and real-world evidence play a crucial role in clinical research and healthcare optimization.
• The use of AI and NLP in processing real-world data is enhancing efficiency and accuracy.

We will be speaking to Dr. Konstantin Glebov, Managing Director of Exosome Consulting, a boutique firm driving steady growth by helping biotech ventures and investors commercialize extracellular vesicle (exosome) technologies. A frequent speaker at industry events and symposia, he introduced the “Exosome 2.0” concept at the ISCT Annual Meeting in Vancouver and has presented on commercialization frameworks at global forums. Dr. Glebov’s scientific expertise centers on exosome roles in central nervous system disorders and rare diseases, including Alexander disease, with a strong focus on diagnostic and biomarker applications. With a PhD in Neuroscience, he now helps to develop business strategies to accelerate opportunities at the intersection of science and market in the emerging extracellular vesicle sector.